Countdown on the Opdivo Patent Cliff: Ono Pharmaceutical's Team of Successors
- Patent expiry for Ono's blockbuster cancer drug Opdivo is approaching
- Opdivo accounts for over half of Ono's revenue, making the cliff existential
- Ono runs a dual track: life-extension strategies plus a squad of successor drugs
- The goal is to turn a cliff into a manageable slope
Japanese pharma's most watched patent-cliff drama enters its countdown: Opdivo, Ono Pharmaceutical's cancer immunotherapy born of Nobel-winning PD-1 research, faces patent expiry with the drug still generating more than half of company revenue—a textbook cliff once biosimilars arrive.
Ono's response runs on two tracks. It is extending Opdivo's life through expanded indications and combination-therapy patent webs to soften the slope, while grooming what Toyo Keizai calls a team-based succession: multiple mid-sized drug candidates sharing the baton rather than one long-shot mega-blockbuster. Opdivo's cash flow funds the licensing deals and in-house pipeline behind that squad.
For pharma investors, Ono is the case study in patent-cliff management—the stock has long priced the cliff, and the variable now is whether successor clinical data and launch timing can fill the gap ahead of Opdivo's decay curve. Japan's drug industry is collectively entering the same generational handover.